Q-omics provides the consensus-scored SF3A3P2 profile across patient tissues and cancer cell-line models. SF3A3P2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, SF3A3P2 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, SF3A3P2 RNA expression shows 12,584 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight LUAD, COAD, and DLBC as cancer lineages where SF3A3P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SF3A3P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SF3A3P2 survival associations across molecular data types. SF3A3P2 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SF3A3P2 RNA expression–survival associations across cancer types. High SF3A3P2 expression shows unfavorable associations in LUAD, LIHC, KICH, MESO and ACC, but favorable associations in SKCM. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for SF3A3P2 RNA expression.
This table summarizes SF3A3P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SF3A3P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SF3A3P2 shows higher tumor expression in COAD, STAD, KIRC, LIHC, BLCA and BRCA. The COAD box plot shows higher SF3A3P2 RNA expression in tumor versus normal tissue (log2 FC = +0.288, t-test p < 0.001).
This table shows molecular features associated with SF3A3P2 in patient tissues and cancer cell lines. In patient samples, SF3A3P2 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
